These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34626075)

  • 21. Optimal two-stage randomized phase II clinical trials.
    Logan BR
    Clin Trials; 2005; 2(1):5-12. PubMed ID: 16279574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    Karrison TG; Maitland ML; Stadler WM; Ratain MJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1455-61. PubMed ID: 17895472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolution of Phase II Oncology Trial Design: from Single Arm to Master Protocol.
    Yu Z; Wu L; Bunn V; Li Q; Lin J
    Ther Innov Regul Sci; 2023 Jul; 57(4):823-838. PubMed ID: 36871111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A seamless phase II/III design with dose optimization for oncology drug development.
    Li Y; Zhang Y; Mi G; Lin J
    Stat Med; 2024 Aug; 43(18):3383-3402. PubMed ID: 38845095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
    Jenkins M; Stone A; Jennison C
    Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase II trial designs with biomarkers.
    Freidlin B; McShane LM; Polley MY; Korn EL
    J Clin Oncol; 2012 Sep; 30(26):3304-9. PubMed ID: 22869885
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A composite design for transition from a preliminary to a full-scale study.
    Lachin JM; Younes N
    Stat Med; 2007 Nov; 26(27):5014-32. PubMed ID: 17577245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design issues of randomized phase II trials and a proposal for phase II screening trials.
    Rubinstein LV; Korn EL; Freidlin B; Hunsberger S; Ivy SP; Smith MA
    J Clin Oncol; 2005 Oct; 23(28):7199-206. PubMed ID: 16192604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. One-sample proportion testing procedures for hypothesis of inequality.
    Zhong W; Zhong B
    J Biopharm Stat; 2013 May; 23(3):604-17. PubMed ID: 23611198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized phase II selection design with order constrained strata.
    Chen Y; Yu M
    Biometrics; 2024 Jan; 80(1):. PubMed ID: 38364810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sample size tables for exact single-stage phase II designs.
    A'Hern RP
    Stat Med; 2001 Mar; 20(6):859-66. PubMed ID: 11252008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting population entering phase III trials: a new stratified adaptive phase II design.
    Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
    Stat Med; 2011 Apr; 30(8):801-11. PubMed ID: 21432875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Between-arm comparisons in randomized Phase II trials.
    Jung SH; George SL
    J Biopharm Stat; 2009; 19(3):456-68. PubMed ID: 19384688
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.
    Yap C; Pettitt A; Billingham L
    BMC Med Res Methodol; 2013 Jul; 13():87. PubMed ID: 23819695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Randomized Phase II Trial Designs in Oncology].
    Yoshimura K
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1561-1566. PubMed ID: 30449838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sample size calculation for multi-arm parallel design with restricted mean survival time.
    Chen Y; Lam KF; Xu J
    Stat Methods Med Res; 2024 Jan; 33(1):130-147. PubMed ID: 38093411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of adaptive designs for single-armed phase II oncology trials.
    Kieser M; Englert S
    J Biopharm Stat; 2015; 25(3):602-15. PubMed ID: 24905363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result?
    Parke T; Marchenko O; Anisimov V; Ivanova A; Jennison C; Perevozskaya I; Song G
    J Biopharm Stat; 2017; 27(3):457-476. PubMed ID: 28281911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.